BRPI1011445B8 - Adenovírus oncolíticos para o tratamento de câncer - Google Patents

Adenovírus oncolíticos para o tratamento de câncer

Info

Publication number
BRPI1011445B8
BRPI1011445B8 BRPI1011445A BRPI1011445A BRPI1011445B8 BR PI1011445 B8 BRPI1011445 B8 BR PI1011445B8 BR PI1011445 A BRPI1011445 A BR PI1011445A BR PI1011445 A BRPI1011445 A BR PI1011445A BR PI1011445 B8 BRPI1011445 B8 BR PI1011445B8
Authority
BR
Brazil
Prior art keywords
oncolytic adenovirus
adenovirus
oncolytic
cancer treatment
cancer
Prior art date
Application number
BRPI1011445A
Other languages
English (en)
Inventor
GUEDAN CARRIó Sònia
Maria Cascallo Piqueras Manel
Alemany Bonastre Ramon
Original Assignee
Fundacio Inst Dinvestigacio Biomedica De Bellvitge
Fundacio Privada Inst Dinvestigacio Biomedica De Bellvitge
Inst Catala Doncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011445(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacio Inst Dinvestigacio Biomedica De Bellvitge, Fundacio Privada Inst Dinvestigacio Biomedica De Bellvitge, Inst Catala Doncologia filed Critical Fundacio Inst Dinvestigacio Biomedica De Bellvitge
Publication of BRPI1011445A2 publication Critical patent/BRPI1011445A2/pt
Publication of BRPI1011445B1 publication Critical patent/BRPI1011445B1/pt
Publication of BRPI1011445B8 publication Critical patent/BRPI1011445B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ADENOVÍRUS ONCOLÍTICOS PARA O TRATAMENTO DE CÂNCER A invenção se relaciona a um adenovírus oncolítico que compreende uma sequência que codifica uma enzima hialuronidase inserida no seu genoma. Este adenovírus distribui-se de forma mais eficiente pela massa do tumor e, consequentemente, o efeito oncolítico é aumentado. A injeção endovenosa do adenovírus oncolítico da invenção gera regressões no volume do tumor. Portanto, o adenovírus oncolítico da presente invenção é de utilidade para o tratamento de um câncer ou de um estado pré-maligno do mesmo.
BRPI1011445A 2009-05-06 2010-05-05 Adenovírus oncolíticos para o tratamento de câncer BRPI1011445B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
ESP200901201 2009-05-06
PCT/ES2010/000196 WO2010128182A1 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer

Publications (3)

Publication Number Publication Date
BRPI1011445A2 BRPI1011445A2 (pt) 2020-09-15
BRPI1011445B1 BRPI1011445B1 (pt) 2022-10-04
BRPI1011445B8 true BRPI1011445B8 (pt) 2022-10-25

Family

ID=43050014

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011445A BRPI1011445B8 (pt) 2009-05-06 2010-05-05 Adenovírus oncolíticos para o tratamento de câncer

Country Status (15)

Country Link
US (3) US10316065B2 (pt)
EP (1) EP2428229B2 (pt)
JP (1) JP2012525833A (pt)
KR (1) KR101878274B1 (pt)
CN (2) CN107252438A (pt)
AU (1) AU2010244348B2 (pt)
BR (1) BRPI1011445B8 (pt)
CA (1) CA2761183C (pt)
ES (2) ES2385251B1 (pt)
FI (1) FI2428229T4 (pt)
HK (1) HK1244679A1 (pt)
MX (1) MX2011011818A (pt)
PL (1) PL2428229T5 (pt)
RU (1) RU2536931C2 (pt)
WO (1) WO2010128182A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN103405480B (zh) * 2013-05-03 2015-11-25 浙江理工大学 10-羟基喜树碱-丁二酸与腺病毒结合物及制法和用途
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
KR102272932B1 (ko) * 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
CN104946601A (zh) * 2015-05-28 2015-09-30 金宁一 重组溶瘤腺病毒及其应用
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102323872B1 (ko) * 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
KR20240011868A (ko) * 2016-04-29 2024-01-26 이노비오 파마수티컬즈, 인크. 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN109982709A (zh) * 2016-11-17 2019-07-05 Vcn生物科学有限公司 病毒载体在治疗视网膜母细胞瘤中的用途
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
EP3708657A4 (en) 2017-11-08 2021-08-25 Kagoshima University ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
AU2019208892B2 (en) * 2018-01-19 2022-02-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
WO2019174610A1 (zh) * 2018-03-14 2019-09-19 蔡立刚 一种溶瘤病毒、合成dna序列及其应用
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
RU2753742C1 (ru) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
CN114703186B (zh) * 2022-03-31 2023-08-29 四川大学 肿瘤特异性启动子及其应用
CN117379389B (zh) * 2022-07-12 2026-03-06 四川大学 血小板-溶瘤病毒复合物、其制备方法及其应用
WO2024062372A1 (en) * 2022-09-19 2024-03-28 Theriva Biologics, S.L. Combination therapies with oncolytic adenovirus and topoisomerase i inhibitors or prodrugs thereof
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
KR20260077739A (ko) * 2023-09-20 2026-05-28 테리바 바이오로직스 에스.엘. 암의 치료에 사용하기 위한 종양용해성 아데노바이러스와 토포아이소머라제 i 저해제

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
EP0872552A1 (en) 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20040048821A1 (en) 1997-06-27 2004-03-11 Cold Spring Harbor Laboratory Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
CN1304316A (zh) 1998-02-06 2001-07-18 亚拉巴马大学伯明翰分校研究基金会 在纤维结的hi环中含有异源肽表位的腺病毒载体
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
CZ301506B6 (cs) 1998-10-15 2010-03-31 Canji, Inc. Selektivne se replikující rekombinantní virový vektor a zpusob jeho prípravy, farmaceutická formulace, zpusob usmrcení bunky s defektní dráhou, transformovaná bunka a promotor reagující na dráhu p53 a TGF-ß
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
WO2000029599A1 (en) 1998-11-18 2000-05-25 Canji, Inc. Viral vectors with late transgene expression
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
EP1180932B1 (en) 1999-05-12 2012-01-11 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US7078030B2 (en) 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
WO2001036650A2 (en) 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020164715A1 (en) 2000-07-10 2002-11-07 Lin Ji Chromosome 3p21.3 genes are tumor suppressors
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
CA2439185A1 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constructs
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
AU2003241268A1 (en) 2002-02-05 2003-09-09 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003220115A1 (en) 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2519680A1 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2005018332A1 (en) * 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
US20070036721A1 (en) * 2003-09-23 2007-02-15 Uab Resarch Foundation Methods and compositions for in vivo inflammation monitoring
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US8658778B2 (en) 2005-03-09 2014-02-25 Board Of Regents, The University Of Texas System hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
ATE516370T1 (de) 2005-12-22 2011-07-15 Sloan Kettering Inst Cancer Verfahren zur erfassung von krebszellen unter verwendung eines virus
CN101970650B (zh) * 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
BR112020015488A2 (pt) * 2018-02-08 2020-12-08 Sangamo Therapeutics, Inc. Nucleases alvo-específicas modificadas

Also Published As

Publication number Publication date
HK1167818A1 (en) 2012-12-14
CA2761183A1 (en) 2010-11-11
EP2428229B2 (en) 2025-05-21
PL2428229T3 (pl) 2017-02-28
US20190345204A1 (en) 2019-11-14
MX2011011818A (es) 2012-06-19
BRPI1011445B1 (pt) 2022-10-04
US20250011373A1 (en) 2025-01-09
WO2010128182A1 (es) 2010-11-11
ES2385251A1 (es) 2012-07-20
KR20120049185A (ko) 2012-05-16
AU2010244348A1 (en) 2011-12-01
KR101878274B1 (ko) 2018-07-13
BRPI1011445A2 (pt) 2020-09-15
US20120148535A1 (en) 2012-06-14
RU2536931C2 (ru) 2014-12-27
RU2011149458A (ru) 2013-06-27
US10316065B2 (en) 2019-06-11
ES2600955T5 (en) 2025-10-02
PL2428229T5 (pl) 2025-08-18
ES2385251B1 (es) 2013-05-06
CN107252438A (zh) 2017-10-17
CA2761183C (en) 2019-03-26
EP2428229A1 (en) 2012-03-14
ES2600955T3 (es) 2017-02-13
CN102548584A (zh) 2012-07-04
HK1244679A1 (zh) 2018-08-17
FI2428229T4 (fi) 2025-07-29
AU2010244348B2 (en) 2016-08-11
EP2428229B1 (en) 2016-08-03
JP2012525833A (ja) 2012-10-25
US12129280B2 (en) 2024-10-29

Similar Documents

Publication Publication Date Title
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
BRPI0922301A2 (pt) combinações de inibidor de hsp90
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
EP4523696A3 (en) Enhanced adoptive cell therapy
CL2012000487A1 (es) Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
TN2012000280A1 (en) Methods of administering pirfenidone therapy
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
NI201500062A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
BR112015026244A2 (pt) codificação e decodificação de sinal compatível com versões anteriores híbrido
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
MX2012009030A (es) Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa.
MX2011006290A (es) Compuestos de aza-azuleno.
CR20120035A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
BR112014019399A2 (pt) métodos de tratamento da fibrose
GT201200220A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
IN2014DN08385A (pt)
UY32546A (es) Composiciones y metodos para tratar cancer
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
MX2022015822A (es) Vacunas de cancer dirigidas a muc16 y sus usos.

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (ES) ; INSTITUT CATALA D' ONCOLOGIA (ES)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME E DE SEDE REQUERIDAS ATRAVES DA PETICAO NO 20120049387, DE 31/05/2012, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INSTITUT CATALA D' ONCOLOGIA (ES) ; FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (ES)

B25G Requested change of headquarter approved

Owner name: INSTITUT CATALA D' ONCOLOGIA (ES) ; FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2700 DE 04.10.2022 QUANTO AO TITULO E AO NOME DE UM DOS INVENTORES